Thus, the AACC double genotype of CD147 and DRB1*1501 polymorphisms seems to be a clinically highly specific marker of severity, systemic therapy and radiotherapy of patients with T-cell lymphoma. This evidence concerns the gene HLA-DRB1 and T-cell non-Hodgkin lymphoma.